Pediatric anesthesia & critical care

Impact of patient positioning on the occurrence of perioperative respiratory adverse events in children -a cluster randomised trial – The POSSUM trial

Anaesth Crit Care Pain MedPublished Cluster randomised controlled trial

Authors' conclusion

Overall, standardized perioperative HE30 did not influence the occurrence of PRAE in children undergoing general anaesthesia.

Study context

Population
Children undergoing surgery under GA, managed in-hoursPhase One
Participants
1,935 children
Comparison
HE30 vs no head elevation (NHE)
  • HE30n = 959
  • NHEn = 976reference
Primary endpoint
Overall incidence of PRAE
Methodological detailsprospective, two phases, weekly alternating allocation, Phase One: allocated positions alternated weekly for 8 weeks, Phase Two: 4-week period of routine practice, positioning at clinician's discretion
  • Prospective
  • Two phases
  • Weekly alternating allocation
  • Phase One: allocated positions alternated weekly for 8 weeks
  • Phase Two: 4-week period of routine practice, positioning at clinician's discretion

Primary result

As reported in the abstract

P = 0.42

Further findings

PRAE in patients managed with a tracheal tube (TT) (subgroup)

P = 0.017

OutcomeOR (95% CI)P value
PRAE in patients managed with a tracheal tube (TT) (subgroup)Multivariable1.75 (1.01–3.02)P = 0.04
PRAE, Phase One vs Phase Two (routine practice, n = 905)Both 14%0.93 (0.74–1.17)P = 0.53

Perioperative respiratory adverse events (PRAE), Phase One vs Phase Two (routine practice, n = 905)

NHE and 15-degree head-elevated positions preferred by staff in Phase Two

Original publication

Impact of patient positioning on the occurrence of perioperative respiratory adverse events in children -a cluster randomised trial – The POSSUM trial. Anaesth Crit Care Pain Med. Published 7 July 2026. doi:10.1016/j.accpm.2026.101889

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.